What records are connected here?
- Evidence lanes
- 3
- Source years
- 19
- Drugs@FDA applications
- 1
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
FDA-approved1,2Evidence: Smaller human trialsGut and digestion
Secretin is a 27-amino-acid gut hormone that prompts the pancreas to release bicarbonate-rich fluid. ChiRhoStim contains a synthetic version identical to human secretin.1,2 It is approved as a diagnostic agent, not a treatment: its label covers tests of pancreatic function, testing for gastrin-producing tumors and helping doctors find the pancreatic duct openings during an endoscopic procedure (ERCP).1 In a randomized, placebo-controlled crossover study of 24 patients described in the label, the minor pancreatic duct was reached in 16 with secretin and 2 with placebo.1
| What it is | A synthetic peptide hormone of 27 amino acids with the same sequence as natural human secretin, according to the ChiRhoStim label.1 |
|---|---|
| FDA status | FDA-approved. It is approved for diagnostic use; Drugs@FDA lists ChiRhoStim, NDA 021256, with an original approval date of April 9, 2004. The cited label has no boxed warning.1,2 |
| Human evidence | Small diagnostic studies described in the label, including a randomized, placebo-controlled crossover study in 24 patients undergoing ERCP.1 |
| Evidence strength | Smaller controlled human trials. The cited sources include randomized or otherwise controlled human trials that are fully reported in a journal article or in posted registry results, but none meets the large-trial rule. How this label is assigned |
Secretin is a peptide hormone that the duodenum releases when stomach acid, fats or amino acids reach it. ChiRhoStim contains a synthetic form with the same 27-amino-acid sequence as the natural human hormone.1
In the United States it is the active ingredient of ChiRhoStim, approved under NDA 021256, according to Drugs@FDA.2
The label states that secretin binds to receptors on pancreatic duct cells and opens CFTR channels, so the pancreas secretes large volumes of fluid rich in bicarbonate.1
In people with gastrinoma, a gastrin-producing tumor, secretin raises blood gastrin, while healthy people show little or no change; the label states that this difference is the basis of the gastrinoma test.1
In a randomized, placebo-controlled crossover study of 24 patients with pancreas divisum undergoing ERCP, the minor duct was successfully entered in 16 of 24 with ChiRhoStim and 2 of 24 with placebo, according to the label.1
The label reports that all 21 patients with chronic pancreatitis in three crossover studies had low peak bicarbonate after secretin, while all 35 healthy people tested had normal values.1
In a crossover study of 6 patients with confirmed gastrinoma, all secretin products tested raised gastrin above the diagnostic threshold, and 12 healthy people tested negative, according to the label.1
Evidence-strength label: Smaller controlled human trials. How this label is assigned
Yes, as a diagnostic agent. Drugs@FDA lists ChiRhoStim, application NDA 021256, with an original approval date of April 9, 2004.2
The ChiRhoStim label cited here (DailyMed version dated October 8, 2025, published November 17, 2025) states that it is indicated to stimulate pancreatic secretions to aid in diagnosing pancreatic exocrine dysfunction, to stimulate gastrin secretion to aid in diagnosing gastrinoma, and to help identify the pancreatic duct openings during ERCP.1
The label has no boxed warning and lists no contraindications. It warns that liver disease, earlier vagus nerve surgery, inflammatory bowel disease and some acid-lowering or anticholinergic drugs can distort test results.1
HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Secretin is not among them.3,4
Fixed normal ranges: the label states that normal pancreatic responses vary between investigators and laboratories, and that each site should establish its own ranges.1
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Go deeper
Everything PeptideScanner has collected for Secretin: reviews, official-source readings, registry and literature records, and every change to this profile.
What the trial and literature lists cover. The trials and papers listed for Secretin are a bounded selection, not every registration or paper about Secretin. For the years before Secretin was added, PeptideScanner took at most 25 ClinicalTrials.gov registrations that list Secretin as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 25 PubMed papers that name Secretin in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.
Evidence summary
FDA-approved as ChiRhoStim for pancreatic and gastrinoma testing. The label describes small diagnostic studies, including a randomized, placebo-controlled crossover study of 24 patients undergoing ERCP. It is a diagnostic agent, not a treatment.↗↗
Status sources checked through November 15, 2026. See status sources and coverage →
Explore this profile’s cited source records →
An editorial human-evidence summary has not yet been published.
Living status brief
FDA-approved as ChiRhoStim for pancreatic and gastrinoma testing. The label describes small diagnostic studies, including a randomized, placebo-controlled crossover study of 24 patients undergoing ERCP. It is a diagnostic agent, not a treatment.↗↗
The cited status sources were checked through November 15, 2026. This answer changes only through the profile’s visible version and correction history.
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
Literature metadata · source date November 1, 2026
Secretin: a hormone for HCO3- homeostasis.↗Added to PeptideScanner November 16, 2026Literature metadata · added November 16, 2026
Secretin: a hormone for HCO3- homeostasis.↗Source date November 1, 2026Clinical trials · added November 16, 2026
ClinicalTrials.gov record NCT02000089↗Source date October 22, 2026Literature metadata · added November 16, 2026
Secretin as a treatment for autism: a review of the evidence.↗Source date October 11, 2026PeptideScanner currently has no selected safety records connected to this profile. That is a collection gap, not evidence that no such records exist.
PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.
Evidence Map v1
This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.
10 of 12 selected trial records include at least one phase value; 12 of 12 include a status value in the retained structured contract.
A phase value is unavailable here for 2 selected records; this is not counted as “no phase.”
25 of 25 selected PubMed records include attributed title, venue, publication date, and publication-type fields.
Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.
Research hub
PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.
PeptideScanner retained ClinicalTrials.gov record NCT00438906 at 2026-11-16T01:34:15.953Z. Its registry update date was 2021-06-18, and PeptideScanner's reviewed identity mapping was secretin.
PeptideScanner retained ClinicalTrials.gov record NCT01087801 at 2026-11-16T01:34:15.953Z. Its registry update date was 2011-12-06, and PeptideScanner's reviewed identity mapping was secretin.
PeptideScanner retained ClinicalTrials.gov record NCT01134848 at 2026-11-16T01:34:15.953Z. Its registry update date was 2010-06-02, and PeptideScanner's reviewed identity mapping was secretin.
25 with attributed title, venue, publication-date, and type metadata.
0 public history versions across these dated registry records; status labels apply only to each cited observation.
Original-submission application metadata connected by exact reviewed active-ingredient names.
FDA- and HHS-attributed document metadata connected by exact reviewed peptide-name matches, with official GovInfo PDFs.
Selected records span August 18, 2003 to November 1, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.
These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.
Literature metadata
PubMed lists PMID 38221598 in Pflugers Archiv : European journal of physiology as Journal Article, Review, Research Support, Non-U.S. Gov't, with publication-date metadata of 2024-01-15 (day precision). PeptideScanner associated the retained record with the identity slug secretin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT02000089 at 2026-11-16T01:34:15.953Z. Its registry update date was 2026-10-22, and PeptideScanner's reviewed identity mapping was secretin.↗
Literature metadata
PubMed lists PMID 15628608 in Journal of autism and developmental disorders as Journal Article, Meta-Analysis, Review, with publication-date metadata of 2004-10 (month precision). PeptideScanner associated the retained record with the identity slug secretin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT05659147 at 2026-11-16T01:34:15.953Z. Its registry update date was 2026-03-18, and PeptideScanner's reviewed identity mapping was secretin.↗
Literature metadata
PubMed lists PMID 40645521 in The Journal of biological chemistry as Journal Article, Review, Research Support, N.I.H., Extramural, with publication-date metadata of 2025-07-09 (day precision). PeptideScanner associated the retained record with the identity slug secretin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 21464196 in Pediatrics as Journal Article, Research Support, N.I.H., Extramural, Systematic Review, with publication-date metadata of 2011-04-04 (day precision). PeptideScanner associated the retained record with the identity slug secretin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT03404661 at 2026-11-16T01:34:15.953Z. Its registry update date was 2023-06-06, and PeptideScanner's reviewed identity mapping was secretin.↗
Literature metadata
PubMed lists PMID 36187484 in Frontiers in cell and developmental biology as Journal Article, Review, with publication-date metadata of 2022-09-14 (day precision). PeptideScanner associated the retained record with the identity slug secretin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 16527763 in Cerebellum (London, England) as Journal Article, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2006 (year precision). PeptideScanner associated the retained record with the identity slug secretin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 32737904 in Hepatology (Baltimore, Md.) as Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S., Review, with publication-date metadata of 2020-11-19 (day precision). PeptideScanner associated the retained record with the identity slug secretin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 25332973 in Annals of translational medicine as Journal Article, Review, with publication-date metadata of 2013-10 (month precision). PeptideScanner associated the retained record with the identity slug secretin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 21718310 in British journal of pharmacology as Journal Article, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2012-05 (month precision). PeptideScanner associated the retained record with the identity slug secretin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Citations
Numbered markers in the text point here. Each link opens the original public record.
DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026
Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026